Author: Xia, Shuai; Yan, Lei; Xu, Wei; Agrawal, Anurodh Shankar; Algaissi, Abdullah; Tseng, Chien-Te K.; Wang, Qian; Du, Lanying; Tan, Wenjie; Wilson, Ian A.; Jiang, Shibo; Yang, Bei; Lu, Lu
Title: A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike Document date: 2019_4_10
ID: 3c5ab73l_23
Snippet: We further compared the potential histopathological changes of EK1-and PBS-treated groups 4 weeks after administration. The hematoxylin and eosin staining of lung, liver, kidney, and spleen sections from mice treated with EK1 at different doses exhibited no pathological abnormality, when compared to control mice treated with PBS ( fig. S3H ). None of these organs showed evidence of cell degeneration, necrosis, or infiltration of inflammatory fact.....
Document: We further compared the potential histopathological changes of EK1-and PBS-treated groups 4 weeks after administration. The hematoxylin and eosin staining of lung, liver, kidney, and spleen sections from mice treated with EK1 at different doses exhibited no pathological abnormality, when compared to control mice treated with PBS ( fig. S3H ). None of these organs showed evidence of cell degeneration, necrosis, or infiltration of inflammatory factors. Hence, EK1 appears to be generally safe via nasal application.
Search related documents:
Co phrase search for related documents, hyperlinks ordered by date